



NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the “**AGM**”) of Clearbridge Health Limited (the “**Company**”) will be held by way of electronic means on Tuesday, 26 April 2022 at 10.00 a.m. for the following purposes:

Ordinary Business

1. To receive and adopt the audited financial statements of the Company for the financial year ended 31 December 2021 (“**FY2021**”), the directors’ statement and the auditors’ report thereon.
(Resolution 1)
2. To approve the payment of directors’ fees of S\$180,000 for the financial year ending 31 December 2022 (“**FY2022**”), payable quarterly in arrears.
(See Explanatory Note 1) **(Resolution 2)**
3. To re-elect Mr Yee Pinh Jeremy who is retiring pursuant to Regulation 98 of the Company’s constitution (the “**Constitution**”) as a director of the Company (“**Director**”) and who being eligible, offers himself for re-election.
(See Explanatory Note 2) **(Resolution 3)**
4. To re-elect Mr Andrew John Lord who is retiring pursuant to Regulation 98 of the Constitution as a Director and who being eligible, offers himself for re-election.
(See Explanatory Note 3) **(Resolution 4)**
5. To re-appoint Messrs Ernst & Young LLP as the Company’s auditor and to authorise the Directors to fix its remuneration.
(Resolution 5)
6. To transact any other ordinary business which may be properly transacted at the AGM.

Special Business

To consider and, if thought fit, to pass the following resolutions as ordinary resolutions, with or without any modifications:

7. Authority to allot and issue shares

“THAT pursuant to Section 161 of the Companies Act 1967 of Singapore (the “**Act**”) and Rule 806 of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rule of Catalyst (“**Catalist Rules**”) and the Constitution, the Directors be and hereby authorised to:

- I. (a) allot and issue shares in the capital of the Company (“**Shares**”) whether by way of rights, bonus or otherwise; and/or
- (b) make or grant offers, agreements or options (collectively, “**Instruments**”) that might or would require Shares to be issued including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures, or other instruments convertible into Shares;

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and



NOTICE OF ANNUAL GENERAL MEETING

- II. (notwithstanding that the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instrument made or granted by the Directors while this Resolution was in force,

provided that:

- (a) the aggregate number of Shares to be issued pursuant to this Resolution (including Shares to be issued in pursuance of Instruments, made or granted pursuant to this Resolution), shall not exceed 100% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (b) below), of which the aggregate number of Shares to be issued other than on a pro-rata basis to the existing shareholders of the Company ("**Shareholders**") shall not exceed 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (b) below);
- (b) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) that may be issued under sub-paragraph (a) above, the percentage of the issued Shares shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) at the time this Resolution is passed, after adjusting for:
- (i) new Shares arising from the conversion or exercise of any convertible securities;
- (ii) new Shares arising from exercising of share options or vesting of share awards, provided that such share options or share awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
- (iii) any subsequent bonus issue, consolidation or subdivision of Shares;

Adjustments in accordance with Rule 806(3)(a) or Rule 806(3)(b) of the Catalist Rules are only to be made in respect of new Shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of the resolution approving the mandate;

- (c) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), and all applicable legal requirements under the Act and the Constitution for the time being; and
- (d) the authority conferred by this Resolution shall, unless revoked or varied by the Company in a general meeting, continue to be in force until the conclusion of the next AGM or the date by which the next AGM is required by law to be held, whichever is earlier."

(See [Explanatory Note 4](#))

(Resolution 6)

NOTICE OF ANNUAL GENERAL MEETING

8. Authority to grant awards and to allot and issue Shares pursuant to the Clearbridge Health Performance Share Plan

“THAT pursuant to Section 161 of the Act, authority be and is hereby given to the Directors to:

- I. offer and grant awards (“**Awards**”) from time to time in accordance with the provisions of the Clearbridge Health Performance Share Plan (the “**PSP**”); and
- II. allot and issue from time to time such number of new Shares as may be required to be issued pursuant to the vesting of Awards granted under the PSP,

provided always that the aggregate number of Shares issued and issuable pursuant to the Awards granted under the PSP, when added to (i) the number of Shares issued and issuable and/or transferred or transferable in respect of all Awards granted thereunder; and (ii) all other Shares issued and issuable and/or transferred or transferable in respect of all share options granted or share awards granted under any other share incentive schemes or share plans adopted by the Company, shall not exceed 15% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) from time to time; and that such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next AGM or the date by which the next AGM is required by law to be held, whichever is earlier.

(See Explanatory Note 5)

(Resolution 7)

By Order of the Board

Lim Sim Ving
Company Secretary
Singapore
11 April 2022



NOTICE OF ANNUAL GENERAL MEETING

NOTES:

1. Shareholders may access a copy of the Company's FY2021 annual report at the Company's website at the URL <https://clearbridgehealth.com/about-us/corporate-information/investor-relations/#annual-reports> and the SGX website at the URL <https://www.sgx.com/securities/company-announcements>.
2. In view of the safe distancing regulations to hold physical meetings and to minimise physical interactions and COVID-19 transmission risks, the Company will be conducting its AGM wholly **by electronic means** in accordance with COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts and Debentures Holders) Order 2020 and the Joint Statement of the Accounting and Corporate Regulatory Authority, Monetary Authority of Singapore and Singapore Exchange Regulation issued on 4 February 2022 titled "Guidance on the Conduct of General Meetings Amid Evolving COVID-19 Situation". Printed copies of this Notice of AGM will not be sent to members. Instead, this Notice of AGM will be published on the Company's website at the URL: <https://clearbridgehealth.com/about-us/corporate-information/investor-relations/#annual-reports>, and on SGXNet at the URL: <https://www.sgx.com/securities/company-announcements>.
3. Alternative arrangements are instead put in place to allow Shareholders to participate in the AGM by:

- (a) Electronically assessed via "live" audio-visual webcast or "live" audio-only stream.

Shareholders and investors who hold Shares through relevant intermediaries ("**Relevant Intermediaries**") (as defined in Section 181 of the Act) (including the supplementary retirement scheme ("**SRS Investors**"); together the "**Investors**") may register for an account to attend the AGM by way of a "live" webcast comprising both video (audio and visual) and audio only stream ("**Webcast**") at the URL: <https://online.meetings.vision/clearbridge-agm-registration> ("**Website**"). Registration for the Webcast must be completed not later than 72 hours before the time fixed for the AGM, being **23 April 2022 at 10.00 a.m. (Singapore time)** ("**Cut-Off Date**") in the following manner:

- (i) Individual persons with Shares entered against their name in the Depository Register, individual persons with Shares registered in their name in the Register of Members and SRS Investors shall complete the section entitled "*Individual Shareholders*" on the Website.
- (ii) Corporations should authorise its corporate representative by way of certificate of appointment of corporate representative and complete the section entitled "*Corporate Shareholders*" on the Website.

Following successful registration, details on how to join the Webcast (including the assigned username and password) will be sent to you at the electronic mail address specified in your pre-registration details by **25 April 2022, 10.00 a.m. (Singapore time)** ("**Email Notification**"). If you have pre-registered by the Cut-Off Date but did not receive the Email Notification, you should contact the Company's Share Registrar, Tricor Barbinder Share Registration Services at SG.IS.Enquiry@sg.tricorglobal.com.

Investors (other than SRS Investors) will not be able to register on the Website and should contact the Relevant Intermediary through which they hold Shares as soon as possible in order to make the necessary arrangements for them to participate in the AGM.

- (b) Submission of questions in advance of the AGM.

Shareholders and Investors will not be able to ask questions "live" via the Webcast. Instead, Shareholders and Investors may submit any questions related to the resolutions to be tabled for approval at the AGM (i) via electronic mail to the Company at the email address ShareholderQueries@clearbridgehealth.com; or (ii) via post to the Company's Share Registrar, Tricor Barbinder Share Registration Service at 80 Robinson Road, #11-02, Singapore 068898 within 7 calendar days from the Notice of AGM, i.e. no later than **18 April 2022 at 5.00 p.m. (Singapore time)**.

Investors (other than SRS Investors) will not be able to submit questions relating to the business of the AGM via the above. Instead, they should approach their Relevant Intermediaries as soon as possible in order for their Relevant Intermediaries to make the necessary arrangements for them to submit questions in advance of the AGM.

The Company will announce the responses to substantial questions received from Shareholders and Investors on the Company's website at the URL: <https://clearbridgehealth.com> and on SGXNet at the URL: <https://www.sgx.com/securities/company-announcements>, at least 48 hours prior to the Cut-off Date for the lodgement of the proxy forms, i.e. by **20 April 2022**.

- (c) Voting by appointing the Chairman of the AGM as proxy.

Due to the current COVID-19 situation in Singapore, a member will not be able to attend the AGM in person. A member will also not be able to vote "live" on the resolutions to be tabled for approval at the AGM. A member must appoint the Chairman of the AGM as his/her/its proxy to vote on his/her/its behalf at the AGM if such member wishes to exercise his/her/its voting rights at the AGM. The accompanying proxy form for the AGM may be accessed at the Company's website at the URL: <https://clearbridgehealth.com/about-us/corporate-information/investor-relations/#annual-reports> and on SGXNet at the URL: <https://www.sgx.com/securities/company-announcements>.

Where a member appoints the Chairman of the AGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in respect of a resolution in the proxy form, failing which appointment of the Chairman as proxy for that resolution will be treated as invalid.

NOTICE OF ANNUAL GENERAL MEETING

The proxy form appointing the Chairman of the AGM as proxy must be received by the Company **not later than the Cut-off Date being 23 April 2022 at 10.00 a.m. (Singapore time)**, (i) by email to ProxyFormSubmission@clearbridgehealth.com (e.g. enclosing a clear scanned completed and signed proxy form); or (ii) by post to the office of the Company's Share Registrar, Tricor Barbinder Share Registration Services at 80 Robinson Road, #11-02, Singapore 068898.

The proxy form is not valid for use by Investors (including SRS Investors) and shall be ineffective for all intents and purposes if used or purported to be used by them. Investors (including SRS Investors) should instead contact their Relevant Intermediaries as soon as possible to specify their voting instructions. SRS Investors should approach their respective SRS operators at least 7 working days before the AGM (by **13 April 2022, 5.00 p.m. (Singapore time)**) and the SRS operators will submit the proxy form on their behalf.

Relevant Intermediaries shall complete the proxy form submission in respect of the investors (including SRS Investors), and provide to the Company a consolidated list of investors, including SRS Investors ("**Attendees**"), together with the following information: (i) Name of Attendee; (ii) NRIC number/passport number/company registration number; (iii) email address; and (iv) the interests held in the Company by each Attendee for registration by email to ProxyFormSubmission@clearbridgehealth.com no later than **the Cut-off Date being 23 April 2022 at 10.00 a.m. (Singapore time)**.

A member who wishes to submit a proxy form must first download, complete and sign the proxy form, before submitting it by post to the address provided above, or before scanning and sending it by electronic mail to the email address provided before, where relevant.

In view of the current COVID-19 situation, members are strongly encouraged to submit completed and signed proxy forms electronically via electronic mail.

4. The proxy form appointing a proxy must be under the hand of the appointor or of his attorney duly authorised in writing. Where the proxy form is executed by a corporation, it must be executed either under its common seal (or by the signatures of authorised persons in the manner as set out under the Act as an alternative to sealing) or under the hand of an attorney or an officer of the corporation duly authorised.
5. Where the proxy form is signed on behalf of the appointor by an attorney, the power of attorney (or other authority) or a duly certified copy thereof must (failing previous registration with the Company) be lodged with the proxy form, failing which the proxy form may be treated as invalid.
6. A depositor shall not be regarded as a member of the Company entitled to attend and vote at the AGM unless his/her name appears on the Depository Register not less than 72 hours before the time of the AGM.

EXPLANATORY NOTES:

- (1) Resolution 2 in item 2 above, if passed, will facilitate the payment of Directors' fees of S\$180,000 for FY2022 on a quarterly basis in arrears. The amount of Directors' fees is computed based on the anticipated number of board and board committee meetings for FY2022, including the attendance and positions held by all of the Non-Executive Directors in various board committees, and assuming that all Non-Executive Directors will hold office for the full financial year. In the event the amount of Directors' fees proposed is insufficient, for example in the event of unscheduled board meetings and/or enlarged board sizes, approval will be sought at the next AGM for such additional fees before payments are made to the Directors to meet the shortfall.
- (2) In relation to Resolution 3 in item 3 above, Mr Yee Pinh Jeremy will, upon re-election as a Director, remain as the Executive Director and Chief Executive Officer of the Company ("**CEO**"), and a member of the Nomination Committee.

Detailed information on Mr Yee Pinh Jeremy can be found in the Company's FY2021 annual report.

Details on Mr Yee Pinh Jeremy

Date of Appointment: 15 May 2017

Date of last re-appointment (if applicable): 25 April 2019

Age: 52

Country of principal residence: Singapore

The board of directors' ("**Board**") comments on this appointment (including rationale, selection criteria, and the search and nomination process): The re-election of Mr Yee Pinh Jeremy as Executive Director and CEO was recommended by the Nominating Committee ("**NC**") and approved by the Board, after taking into consideration Mr Yee Pinh Jeremy's qualifications, expertise, experience and overall contribution since he was appointed as a Director.

Whether appointment is executive, and if so, the area of responsibility: Yes, Mr Yee is responsible for identifying and implementing company-wide business growth strategies and overseeing all aspects of the Group's growth and operating functions.

Job Title: Executive Director and CEO, and a member of Nominating Committee

Professional qualifications: Please refer to the "Board of Directors" section in the Company's FY2021 annual report



NOTICE OF ANNUAL GENERAL MEETING

Working experience and occupation(s) during the past 10 years: Please refer to the "Board of Directors" section in the Company's FY2021 annual report

Other Principal Commitments, including Directorships: Please refer to the "Board of Directors" section in the Company's FY2021 annual report

Shareholding interest in the listed issuer and its subsidiaries: Direct interest in 12,597,773 Shares; Deemed interest in 14,578,200 Shares

Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries: None

Conflict of interest (including any competing business): None

Undertaking (in the format set out in Appendix 7H) under Rule 720(1) has been submitted to the listed issuer

Yes No

Items (a) to (k) of Appendix 7F of the Catalist Rules: There is no change to the declaration, which was disclosed in the Company's offer document dated 11 December 2017.

- (3) In relation to Resolution 4 in item 4 above, Mr Andrew John Lord will, upon re-election as a Director, remain as the Lead Independent Director, Chairman of the Remuneration Committee, and a member of the Audit and Nomination Committees. The Board considers him to be independent for the purpose of Rule 704(7) of the Catalist Rules.

Detailed information on Mr Andrew John Lord can be found in the Company's FY2021 annual report.

Details on Mr Andrew John Lord

Date of Appointment: 20 November 2017

Date of last re-appointment (if applicable): 25 April 2019

Age: 62

Country of principal residence: Australia

The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process): The re-election of Mr Andrew John Lord as Independent Director was recommended by the NC and approved by the Board, after taking into consideration Mr Andrew John Lord's qualifications, expertise, experience and overall contribution since he was appointed as a Director.

Whether appointment is executive, and if so, the area of responsibility: Non-executive

Job Title: Lead Independent Director, Chairman of the Remuneration Committee, and a member of Audit and Nominating Committees

Professional qualifications: Please refer to the "Board of Directors" section in the Company's FY2021 annual report

Working experience and occupation(s) during the past 10 years: Please refer to the Board of Directors section in the Company's FY2021 annual report

Other Principal Commitments, including Directorships: Please refer to the "Board of Directors" section in the Company's FY2021 annual report

Shareholding interest in the listed issuer and its subsidiaries: None

Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries: None

Conflict of interest (including any competing business): None

Undertaking (in the format set out in Appendix 7H) under Rule 720(1) has been submitted to the listed issuer

Yes No

Items (a) to (k) of Appendix 7F of the Catalist Rules: There is no change to the declaration, which was disclosed in the Company's offer document dated 11 December 2017.

- (4) The Resolution 6 in item 7 above, if passed, will empower the Directors to allot and issue Shares, make or grant Instruments and to issue Shares pursuant to such Instruments, without seeking any further approval from Shareholders but within the limitations imposed by this Resolution, for such purposes as the Directors may consider would be in the best interests of the Company, from the date of the AGM until the conclusion of the next AGM, or the date by which the next AGM is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is earlier. The aggregate number of Shares (including Shares to be made in pursuance of Instruments made or granted pursuant to this Resolution) to be allotted and issued is not to exceed 100% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) at the time of passing of this Resolution (subject to the adjustments stipulated in item 7(II)(b) above), of which the aggregate number of Shares issued other than on a pro-rata basis to all Shareholders is not to exceed 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) at the time of the passing of this Resolution (subject to the adjustments stipulated in item 7(II)(b) above).

NOTICE OF ANNUAL GENERAL MEETING

- (5) The Resolution 7 in item 8 above, if passed, will empower the Directors to offer and grant Awards under the PSP, and to allot and issue Shares pursuant to the vesting of Awards granted under the PSP, provided that the aggregate number of Shares issued and issuable pursuant to the PSP, when added to (i) the number of Shares issued and issuable and/or transferred or transferable in respect of all Awards granted thereunder; and (ii) all other Shares issued and issuable and/or transferred or transferable in respect of all share options granted or share awards granted under any other share incentive schemes or share plans adopted by the Company, shall not exceed 15% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) from time to time.

PERSONAL DATA PRIVACY

By (a) submitting a proxy form appointing the Chairman of the AGM as proxy to vote at the AGM and/or any adjournment thereof, (b) submitting any questions prior to the AGM, or (c) submitting the pre-registration form in accordance with this Notice, a member of the Company (i) consents to the collection, use and disclosure of the member's personal data by the Company (or its agents or service providers) for the purpose of the processing, administration and analysis by the Company (or its agents or service providers) of proxy forms appointing Chairman of the AGM as proxy for the AGM (including any adjournment thereof); processing the pre-registration forms for purposes of granting access to members to the Live Webcast or Live Audio Stream and providing viewers with any technical assistance, when necessary; addressing substantial and relevant questions from members received in advance of the AGM; the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), recordings and transmitting images and/or voice recording when broadcasting the AGM proceedings through webcast, and in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"), (ii) warrants that where the member discloses the personal data of the member's proxy(ies) and/or representative(s) to the Company (or its agents), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.

This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.